BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 22410704)

  • 1. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.
    Juratli TA; Kirsch M; Robel K; Soucek S; Geiger K; von Kummer R; Schackert G; Krex D
    J Neurooncol; 2012 Jul; 108(3):403-10. PubMed ID: 22410704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
    Taal W; Dubbink HJ; Zonnenberg CB; Zonnenberg BA; Postma TJ; Gijtenbeek JM; Boogerd W; Groenendijk FH; Kros JM; Kouwenhoven MC; van Marion R; van Heuvel I; van der Holt B; Bromberg JE; Sillevis Smitt PA; Dinjens WN; van den Bent MJ;
    Neuro Oncol; 2011 Feb; 13(2):235-41. PubMed ID: 21177338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
    Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
    [No Abstract]   [Full Text] [Related]  

  • 10. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
    Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
    Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.
    Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P
    J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
    Wiestler B; Claus R; Hartlieb SA; Schliesser MG; Weiss EK; Hielscher T; Platten M; Dittmann LM; Meisner C; Felsberg J; Happold C; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Grimm C; Weichenhan D; Tews B; Reifenberger G; Capper D; Müller W; Plass C; Weller M; Wick W;
    Neuro Oncol; 2013 Aug; 15(8):1017-26. PubMed ID: 23595628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
    Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
    J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
    J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
    Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
    Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
    Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
    J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
    Houillier C; Wang X; Kaloshi G; Mokhtari K; Guillevin R; Laffaire J; Paris S; Boisselier B; Idbaih A; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
    Neurology; 2010 Oct; 75(17):1560-6. PubMed ID: 20975057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
    Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
    Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.